Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
27 nov. 2024 04h15 HE
|
Oculis Holding AG
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the...
Oculis to Present at the Stifel 2024 Healthcare Conference
13 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis to Present at the Stifel 2024 Healthcare Conference
13 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
07 nov. 2024 04h00 HE
|
Oculis Holding AG
Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout...
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
07 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Sviss, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Veruleg framvinda þróunarlyfja, þar á meðal innritun í OCS-01 DIAMOND fasa 3 rannsókninni á sjónhimnubjúg í sykursýki (DME) og OCS-05 fasa 2 ACUITY...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
07 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
21 oct. 2024 13h04 HE
|
Oculis Holding AG
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
21 oct. 2024 04h00 HE
|
Oculis Holding AG
Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If...
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
15 oct. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
02 oct. 2024 04h00 HE
|
Oculis Holding AG
Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis’...